Castle Biosciences, Inc.

DB:086 Stock Report

Market Cap: €852.9m

Castle Biosciences Management

Management criteria checks 2/4

Castle Biosciences' CEO is Derek Maetzold, appointed in Sep 2007, has a tenure of 18.17 years. total yearly compensation is $6.94M, comprised of 10.3% salary and 89.7% bonuses, including company stock and options. directly owns 1.12% of the company’s shares, worth €9.54M. The average tenure of the management team and the board of directors is 5.3 years and 5 years respectively.

Key information

Derek Maetzold

Chief executive officer

US$6.9m

Total compensation

CEO salary percentage10.31%
CEO tenure18.2yrs
CEO ownership1.1%
Management average tenure5.3yrs
Board average tenure5yrs

Recent management updates

No updates

Recent updates

CEO Compensation Analysis

How has Derek Maetzold's remuneration changed compared to Castle Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$12m

Jun 30 2025n/an/a

-US$9m

Mar 31 2025n/an/a

-US$5m

Dec 31 2024US$7mUS$716k

US$18m

Sep 30 2024n/an/a

US$6m

Jun 30 2024n/an/a

-US$3m

Mar 31 2024n/an/a

-US$31m

Dec 31 2023US$2mUS$686k

-US$57m

Sep 30 2023n/an/a

-US$76m

Jun 30 2023n/an/a

-US$89m

Mar 31 2023n/an/a

-US$72m

Dec 31 2022US$8mUS$660k

-US$67m

Sep 30 2022n/an/a

-US$53m

Jun 30 2022n/an/a

-US$44m

Mar 31 2022n/an/a

-US$52m

Dec 31 2021US$7mUS$625k

-US$31m

Sep 30 2021n/an/a

-US$30m

Jun 30 2021n/an/a

-US$23m

Mar 31 2021n/an/a

-US$15m

Dec 31 2020US$5mUS$550k

-US$10m

Sep 30 2020n/an/a

-US$3m

Jun 30 2020n/an/a

US$7m

Mar 31 2020n/an/a

US$6m

Dec 31 2019US$4mUS$770k

US$3m

Sep 30 2019n/an/a

US$4m

Jun 30 2019n/an/a

-US$6m

Mar 31 2019n/an/a

-US$8m

Dec 31 2018US$791kUS$410k

-US$10m

Compensation vs Market: Derek's total compensation ($USD6.94M) is above average for companies of similar size in the German market ($USD1.23M).

Compensation vs Earnings: Derek's compensation has increased whilst the company is unprofitable.

CEO

Derek Maetzold (63 yo)

18.2yrs
Tenure
US$6,941,074
Compensation

Mr. Derek J. Maetzold founded Castle Biosciences Incorporated in September 2007 and serves as its President, Chief Executive Officer and Director since September 2007. He serves as the Director at AltheaDx...

Leadership Team

NamePositionTenureCompensationOwnership
Derek Maetzold
Founder18.2yrsUS$6.94m1.12%
€ 9.5m
Frank Stokes
CFO & Treasurer7.9yrsUS$2.31m0.17%
€ 1.4m
Kristen Oelschlager
Chief Operating Officer5.3yrsUS$1.22m0.49%
€ 4.1m
Tobin Juvenal
Chief Commercial Officer5.3yrsUS$2.45m0.30%
€ 2.6m
Camilla Zuckero
Vice President of Investor Relations & Corporate Affairsno datano datano data
Kevin Doman
Vice President of Sales3.4yrsno datano data
Jay Braxton
VP of Marketing & Brand Manager of Uveal Melanoma (UM)1.2yrsno datano data
Keli Greenberg
Vice President of Human Resources5.3yrsno datano data
Matthew Goldberg
Senior Vice President of Medical2.5yrsno datano data
5.3yrs
Average Tenure
60yo
Average Age

Experienced Management: 086's management team is seasoned and experienced (5.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Derek Maetzold
Founder18.2yrsUS$6.94m1.12%
€ 9.5m
Daniel Bradbury
Independent Chairman of the Board13.2yrsUS$297.15k0.076%
€ 645.8k
G. Cole
Independent Director6.9yrsUS$279.65k0.076%
€ 645.8k
Tiffany Olson
Independent Director4.5yrsUS$319.68k0.089%
€ 761.7k
Rodney Cotton
Independent Director1.7yrsUS$550.00k0.048%
€ 411.7k
Kenneth Aldape
Member of Scientific Advisory Boardno datano datano data
Howard Colman
Member of Scientific Advisory Boardno datano datano data
Kimberlee Caple
Independent Director4.3yrsUS$267.15k0.077%
€ 660.2k
Miles Harrison
Independent Director5.6yrsUS$277.15k0.076%
€ 645.8k
Ellen Goldberg
Independent Director4.3yrsUS$264.65k0.094%
€ 801.3k
5.0yrs
Average Tenure
63.5yo
Average Age

Experienced Board: 086's board of directors are considered experienced (5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/06 11:00
End of Day Share Price 2025/11/04 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Castle Biosciences, Inc. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Catherine Ramsey SchulteBaird
Mark MassaroBTIG
Kyle MiksonCanaccord Genuity